Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 29, 2017 08:00 ET | Source: Auris Medical AG

Auris Medical to Present at the 16th Annual Needham Healthcare Conference on April 5

ZUG, Switzerland, March 29, 2017 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...
March 14, 2017 06:00 ET | Source: Auris Medical AG

Auris Medical Provides Business Update and Reports Full Year 2016 Financial Results

Results from first AM-111 Phase 3 trial expected in third quarter of 2017 Addition of AM-125 expands clinical-stage pipeline into vestibular disorders Conference call set for 8 am ET (1 pm...
March 08, 2017 08:00 ET | Source: Auris Medical AG

Auris Medical to Present at the 29th Annual Roth Conference on March 14

ZUG, Switzerland, March 8, 2017 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology,...
March 07, 2017 08:00 ET | Source: Auris Medical AG

Auris Medical to Announce Full Year 2016 Financial Results and Host Conference Call on March 14

Zug, Switzerland, March 7, 2017 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology,...
February 24, 2017 08:00 ET | Source: Auris Medical AG

Auris Medical Receives FDA Fast Track Designation for AM-111 in Acute Sensorineural Hearing Loss

Zug, Switzerland, Feb. 24, 2017 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology,...
February 22, 2017 08:00 ET | Source: Auris Medical AG

Auris Medical and King's College London Extend Tinnitus Collaboration

- Selection of lead compound for AM-102 program planned for 2017 ZUG, Switzerland, Feb. 22, 2017 (GLOBE NEWSWIRE) -- Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to...
February 21, 2017 16:05 ET | Source: Auris Medical AG

Auris Medical Announces Closing of $10 Million Public Offering

Zug, Switzerland, February 21, 2017 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...
February 15, 2017 08:30 ET | Source: Auris Medical AG

Auris Medical Announces Pricing of $10 Million Public Offering

Zug, Switzerland, February 15, 2017 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...
February 14, 2017 16:01 ET | Source: Auris Medical AG

Auris Medical Announces Proposed Public Offering of Common Shares and Warrants

Zug, Switzerland, February 14, 2017 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...
February 03, 2017 06:30 ET | Source: Auris Medical AG

Auris Medical Expands Clinical Development Pipeline with Intranasal Betahistine for the Treatment of Meniere's Disease and Vestibular Vertigo

- Pipeline strengthens with addition of AM-125 as third clinical-stage program- Acquisition of assets related to innovative betahistine product for intranasal delivery - Betahistine is one of the...